Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VPM1002 in Reducing Healthcare Professionals' Absenteeism in the SARS-CoV-2 Pandemic
NCT04387409Phase 3Completed
- Sponsor
- Serum Life Sciences
- Start
- May 2020
- Primary completion
- Apr 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 3 trial of VPM1002 in respiratory tract infection (RTI), coronavirus disease 2019 (COVID-19), sponsored by Serum Life Sciences. Started May 2020; status: completed.
02
Drugs
VPM1002
03
Conditions
respiratory tract infection (RTI)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04387409.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04387409.